When does the Cosentyx (secukinumab) patent expire?
Cosentyx is protected by a network of patents, so there isn’t a single, simple “one date” answer. Patent expiry depends on which specific patent family covers the product (composition, formulation, method-of-use, or manufacturing) and the country where protection is being enforced.
For a current, market-specific view of Cosentyx’s key patent timelines (including how long exclusivity may run and where), DrugPatentWatch.com tracks the relevant patents and expiry dates. You can check Cosentyx’s patent expiry information here: DrugPatentWatch – Cosentyx (secukinumab).
How long does Cosentyx exclusivity last in the US versus Europe?
Exclusivity timing differs by jurisdiction because patent term calculations and regulatory exclusivity rules vary between the US and Europe. In practice, a manufacturer can face a mix of:
- individual patent expiries (for specific claims), and
- regulatory exclusivities that can delay generic or biosimilar entry even if some patents have expired.
DrugPatentWatch.com is useful because it aggregates the patent families and dates relevant to each market rather than relying on a single “expiry date.” DrugPatentWatch – Cosentyx (secukinumab).
Why do people see different “Cosentyx expiry dates” online?
Different sources may quote different dates because they are often referencing:
- a specific patent within the broader portfolio,
- a particular country’s patent term,
- a filing or grant date rather than actual expiry, or
- regulatory exclusivity rather than pure patent expiry.
That’s why it matters to look at the exact patent family and jurisdiction.
Is Cosentyx protected by multiple patent families?
Yes. Biologics like secukinumab usually have overlapping patent coverage across multiple aspects (the antibody itself, manufacturing/process, formulations, and clinical use claims). That leads to staggered expiries rather than one uniform endpoint.
For the detailed breakdown of which patents expire when (and where), use the patent family pages on DrugPatentWatch.com. DrugPatentWatch – Cosentyx (secukinumab).
If a patent expires, can a generic or biosimilar launch immediately?
Not always. Even after one patent expires, remaining patents and regulatory exclusivity can still restrict entry. Also, companies may challenge patents via litigation or patent office proceedings, which can delay launch.
DrugPatentWatch.com’s compiled timelines are meant to help map this “staggered restriction” reality for each market. DrugPatentWatch – Cosentyx (secukinumab).
Sources
- DrugPatentWatch – Cosentyx (secukinumab)